Founder, Managing Director & CEO
For more than 20 years John Kelly has championed the cause of reimagining medical devices to enhance their usability and performance. Before founding Atomo Diagnostics in 2010, John was Chief Operating Officer at ASX listed (now NASDAQ listed) Unilife Corporation, where he led the ‘Unifill’ development team to develop the world’s first glass prefilled drug delivery device with integrated auto retract safety feature. This technology was successfully licensed to Sanofi Aventis. Previously, John led the New Product Implementation Group at ResMed, where he managed the design and commercialisation of the ground-breaking Mirage Swift mask. In addition to his commercial experience, John has an Honours Degree in Mechanical Engineering from the University of Liverpool, a Master’s Degree in Systems Engineering from Queen’s University Belfast, and an Executive MBA from the University of Sydney, where he was awarded the Business School’s inaugural ‘Excellence in Leadership’ scholarship.
Chief Financial Officer
Experienced senior finance executive, lawyer and investment banker. Most recently Will was Chief Financial Officer for property and construction tech company, Verton Technologies. Previously Executive Director at RFC Ambrian where for 11 years he worked closely with companies on fundraising, public markets listings and M&A. Prior to RFC, Will was a Director at PwC over a 10 year period in London and Sydney, and worked at Minter Ellison Lawyers.
Graduate of the AICD, admitted to the Supreme Court of NSW. He holds a Bachelor of Laws, and a Bachelor of Commerce from the University of Adelaide.
Chief Operating Officer
Mark Smith joined Atomo in 2019 as COO, having previously assisted the company in supply chain development.
Mark was co-founder and CEO of a global manufacturing and engineering business, with operations in the UK, China and North America. Highly experienced in managing international supply chains, operations and logistics, he established a Wholly Owned Foreign Entity in Shenzhen in 2003. He oversaw the sale of the business to a listed US corporation in 2013 and continued as CEO until 2016.
Mark has a BA Honours degree in Business Studies from the University of Portsmouth.
Chief Commercial Officer
Fabio Baglioni is the Chief Commercial Officer of Atomo. He is based in Sweden. Fabio has been actively involved in the diagnostics industry for more than ten years, his most recent role being as Vice President Global Sales & Marketing at Cavidi AB since 2012. Cavidi is a Swedish biotech company that develops and market diagnostics products for HIV viral load testing and patient monitoring.
Prior to moving into the healthcare industry, Fabio worked for a number of years for Business Sweden (formerly the Swedish Trade Council) helping Swedish companies succeed abroad.
Fabio holds a Diploma in Marketing & Management, IHM Business School, Stockholm.